Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mA...

Full description

Bibliographic Details
Main Authors: Stefania Crisci, Raffaele Di Francia, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Rosaria De Filippi, Massimiliano Berretta, Paola Rossi, Antonio Pinto
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Oncology
Subjects:
anticancer mAbs
tyrosine kinase inhibitors
tailored therapy
personalized medicine
NHL
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00443/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00443/full

Similar Items